SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-KSB
(Mark One)
[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended September 30, 1999
or
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from _______ to ________
Commission File Number 33-131110 NY
MedTech Diagnostics, Inc.
---------------------------------------------------------
(Name of small business issuer in its charter)
Delaware 11-2831380
- ------------------------------ ------------------
State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
900 Third Avenue, Suite 201, New York, NY 10022
- ----------------------------------------- ---------
(Address of principal executive offices) (Zip code)
(212) 610-2778
------------------------------------------------
(Issuer's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: None
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
past 12 months (or for such shorter periods that the registrant was
required to file such reports), and (2)has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
<PAGE>
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained, to
the best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [X]
State issuer's revenues for its most recent fiscal year: $10,074.
As of January 12, 2000, the aggregate market value of the voting stock held by
non-affiliates of the registrant, based upon the average bid and ask prices of
such stock on that date was $772,200. Shares of Common Stock held by each
officer and director and by each person who owns 10% or more of the outstanding
Common Stock have been excluded in that such persons may be deemed to be
affiliates. This determination of affiliate status is not necessarily conclusive
and does not constitute an admission of affiliate status.
As of January 12, 2000, there were issued and outstanding 281,400,000 shares of
the registrant's Common Stock, par value $.00001 per share.
<PAGE>
PART I
Item 1 - Description of Business
MedTech Diagnostics, Inc. (the "Company"), was incorporated under the laws of
the State of Delaware on October 27, 1986. Prior to 1991, the Company was a
development stage company engaged in research and testing which it hoped would
lead to the development of a home Pap Test Kit. In October 1991, the Company
suspended all operations, except for necessary administrative matters and ceased
to be an operating company. As such, for the years ended September 30, 1999 and
September 30, 1998, the Company had no revenue from operations.
In January 1993, the Company consummated an agreement with Beverley Hills
Bancorp ("BHB") wherein BHB acquired a controlling interest in the Company. On
June 5, 1996, BHB sold its entire interest in the Company's Common Stock to
Messrs. Steven N. Bronson and James S. Cassel. In September, 1998, Mr. Cassel
sold an aggregate of 70,500,000 shares of the Company's Common Stock,
representing Mr. Cassel's entire interest in the Company, to Mr. Bronson. Mr.
Bronson currently owns 141,000,000 shares of the Company's Common Stock,
representing 50.1% of the issued and outstanding shares of the Company's Common
Stock.
The Company currently has no full time employees and its sole officer and
director is Steven N. Bronson. Due to the reduced level of the Company's
operations, no compensation has been paid to Mr. Bronson during the years ended
September 30, 1999 and September 30, 1998.
The Company's management is currently seeking to arrange for a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that this will occur.
In August 1999, the Company negotiated a letter of intent regarding a potential
merger with a third party. In connection with the agreement, the Company made
unsecured loans to the third party aggregating $170,000 which bear interest at
the rate of 10% per annum. The merger negotiations with the third party have
been cancelled and the third party has defaulted under the loan agreement. The
Company has commenced a lawsuit to recover the loans to the third party,
totaling $170,000, plus interest. The action is entitled: MedTech Diagnostics,
Inc. v. Abtech Industries, Inc. and is pending in the New York State Supreme
Court, New York County and has been assigned Index No. 99-605288. There are no
assurances that the Company will be able to recover any of the moneys loaned to
the third party. Accordingly, the Company has valued the loans at $1,000.00 on
its financial statements.
Item 2 - Description of Property
The Company presently maintains its corporate and administrative offices at 900
Third Avenue, Suite 201, New York, New York 10022. The Company utilizes a
portion of the premises occupied by Catalyst Financial Corp., a full service
brokerage investment banking firm, with which Mr. Bronson is a principal. Due to
the curtailed nature of the Company's operations Catalyst Financial Corp. has,
until further notice, waived the payment of rent by the Company. No rent was
paid by the Company during the fiscal years ended September 30, 1999 and
September 30, 1998.
Item 3 - Legal Proceedings
In connection with an agreement with a third party, who was a potential merger
candidate, the Company made unsecured loans to the third party totaling
$170,000, which bear interest at the rate of 10% per annum. The merger
negotiations have been cancelled and the third party has failed to repay the
loans as required by the agreement. The agreement, as amended, between the
Company and the third party is annexed hereto as an Exhibit to this Form 10-KSB
and is expressly incorporated herein by reference. On or about November 22,
1999, the Company commenced a lawsuit to recover the $170,000 loaned to the
third party. The action is entitled: MedTech Diagnostics, Inc. v. Abtech
Industries, Inc. and is pending in the New York State Supreme Court, New York
County and has been assigned Index No. 99-605288. There are no assurances that
the Company will be able to recover any of the moneys loaned to the third party.
The Company is not a party to any other material legal proceedings.
<PAGE>
Item 4 - Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of security holders by the Company during
the fourth quarter of the fiscal year covered by this report.
PART II
Item 5 - Market for Common Stock and Related Stockholder Matters
The Company's Common Stock, par value $.00001 per share, is traded in the
over-the counter market.
The following table sets forth the range of high and low closing bid prices for
the Company's Common Stock for the periods indicated as reported by the National
Quotation Bureau, Inc. These prices represent quotations between dealers, do not
include retail markups, mark down or commissions, and do not necessarily
represent actual transactions.
Bid Price
----------------------
Calendar Years Low High
------ -------
1999: First Quarter $.0000 $.0000
Second Quarter $.0000 $.0000
Third Quarter $.0010 $.0010
Fourth Quarter $.0010 $.0313
1998: First Quarter $.0001 $.0001
Second Quarter $.0001 $.0001
Third Quarter $.0001 $.0001
Fourth Quarter $.0000 $.0000
As of January 12, 2000, the National Quotation Bureau, Inc. reported that the
closing bid and ask prices on the Company's Common Stock were $.001 and $.01,
respectively.
As of January 12, 2000, the Company's Common Stock was held by approximately 120
record holders, who the Company believes are held for in excess of 300
beneficial holders.
The Company has never paid any cash dividends on its Common Stock and does not
anticipate paying any cash dividends in the foreseeable future.
Item 6 - Management's Discussion and Analysis
The following discussion and analysis provides information which the Company's
management believes to be relevant to an assessment and understanding of the
Company's results of operations and financial condition. This discussion should
be read together with the Company's financial statements and the notes to
financial statements, which are included in this report.
General
In October 1991, the Company suspended all operations except for necessary
administrative matters and ceased to be an operating company. As such, for the
fiscal year ended September 30, 1999, the Company had no revenues from
operations. Given the virtual suspension of the Company's operations except for
necessary administrative matters, the Company's sole officer has waived
compensation.
<PAGE>
Results of Operations
During the year ended September 30, 1999 ("Fiscal 99"), the Company earned
interest and dividends of $10,074 as compared to $8,337 of interest and
dividends earned in the year ended September 30, 1998 ("Fiscal 98"), an increase
of $1,737. During Fiscal 99, the Company incurred general and administrative
expenses of $208,874, an increase of $195,303 over Fiscal 98 expenses of
$13,571. The increase was primarily due to the loan and expenses associated with
the Company's agreement with a third party, whereby the Company loaned $170,000
to the third party in contemplation of consummating a merger for the Company.
The agreement, as amended, between the Company and the third party is annexed
hereto as an Exhibit to this Form 10-KSB and is expressly incorporated herein by
reference. The third party failed to satisfy the conditions precedent to
consummating a merger with the Company, thus causing the $170,000 loan to become
due and payable. The third party has defaulted on the loan. On November 22,
1999, the Company commenced a legal action to recover the $170,000 from the
third party, but there can be no assurances that the Company will recover any
part thereof. As such, the Company has recorded an adjustment to its financial
statements of $169,000 as a provision for bad debt.
Liquidity and Capital Resources
During Fiscal 99, the Company satisfied its working capital needs from cash on
hand at the beginning of the year and cash generated from interest income during
the year. As of September 30, 1999, the Company had working capital of $21,098.
This working capital may not be sufficient to provide the Company with
sufficient capital while it seeks a merger, acquisition or other arrangement by
and between the Company and a viable operating entity. The Company may need
additional funds in order to effectuate a merger, acquisition or other
arrangement by and between the Company and a viable operating entity, although
there is no assurance that the Company will be able to obtain such additional
funds, if needed. Even if the Company is able to obtain additional fund there is
no assurance that the Company will be able to effectuate a merger, acquisition
or other arrangement by and between the Company and a viable operating entity.
As noted above, in August 1999, the Company negotiated an agreement regarding a
potential merger with a third party. In accordance with the agreement the
Company loaned such third party $170,000, with interest accruing at the rate of
10% per annum. The agreement, as amended, between the Company and the third
party is annexed hereto as an Exhibit to this Form 10-KSB and is expressly
incorporated herein by reference. Merger negotiations between the Company and
the third party have been terminated and the third party has defaulted on the
loan. The Company has commenced a lawsuit to recover the $170,000 from the third
party, with interest. The action is entitled: MedTech Diagnostics, Inc. v.
Abtech Industries, Inc. and is pending in the New York State Supreme Court, New
York County and has been assigned Index No. 99-605288. There are no assurances
that the Company will be able to recover any of the moneys loaned to the third
party. Accordingly, the Company has recorded an adjustment on its financial
statements, for bad debts, and valued the $170,000 loan receivable at $1,000.00.
The Company's management is continuing to seek to arrange for a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that this will occur.
Item 7 - Financial Statements
The financial statements and related notes are included as part of this report
as indexed in the appendix on page 3.
<PAGE>
Item 8 - Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
As previously disclosed in the Company's Form 8-K, dated December 29, 1999, the
Company dismissed Grant Thornton LLP as its independent accountants and engaged
Kaufman, Rossin & Co. as its new independent accountants, effective on December
8, 1999. As noted in the Form 8-K, dated December 29, 1999, there were no
disagreements or disputes between the Company and its accountants concerning
accounting methods or procedures and/or financial disclosure. The Company's Form
8-K, dated December 29, 1999 is incorporated herein by reference.
PART III
Item 9 - Directors and Executive Officers; Compliance With Section 16(a) of the
Exchange Act
The executive officers and directors of the Company are as follows:
Name Age Position
- ----- ----- ----------
Steven N. Bronson 34 Sole Officer and Director
Steven N. Bronson has served as the Company's sole officer and director since
September, 1998 and as the Company's Chairman, President and Chief Executive
Officer during the period of June, 1996 through September, 1998. Due to the
curtailed nature of the Company's business activities, Mr. Bronson does not
devote his full time to the affairs of the Company. Mr. Bronson is the President
of Catalyst Financial Corp., a full service securities brokerage and investment
banking firm and has held that position since September 24, 1998. During the
period of 1991 through September 23, 1998, Mr. Bronson was President of Barber &
Bronson Incorporated, a full service securities brokerage investment banking
firm. In addition, Mr. Bronson is the Chairman of the Board of Directors of
Mikron Instrument Company, Inc., a publicly traded corporation.
The Company's By-Laws provide for the election of directors at the annual
meeting of shareholders, such directors to hold office until the next annual
meeting and until their successors are duly elected and qualified. The By-Laws
also provide that the annual meeting of shareholders be held each year at such
time, date and place as the Board of Directors shall determine by resolution.
Directors may be removed at any time for cause by the Board of Directors and
with or without cause by a majority of the votes cast by the shareholders
entitled to vote for the election of directors.
Officers will normally be elected at the annual meeting of the Board of
Directors held immediately following the annual meeting of shareholders, to hold
office for the term for which elected and until their successors have been duly
elected and qualify. Officers may be removed by the Board of Directors at any
time with or without cause.
For the year ended September 30, 1999, based solely on its review of copies of
Forms 3 and 4 received by it, and written representations that no Forms 5 were
required, the Company believes that these Forms were timely filed pursuant to
Section 16 of the Securities Exchange Act of 1934.
Item 10 - Executive Compensation
Due to the reduced level of the Company's operations, no compensation has been
paid to any of the Company's executive officers during the years ended
September 30, 1999 and September 30, 1998.
The Company does not presently have any option, bonus, retirement or profit
sharing plans.
<PAGE>
Item 11 - Security Ownership of Certain Beneficial Owners and Management
The following table sets forth certain information regarding beneficial
ownership of Common Stock as of January 12, 2000 by (i) each person or entity
known by the Company to beneficially own more than 5% of the outstanding Common
Stock, (ii) each director, (iii) each executive officer, and (iv) all directors
and executive officers of the Company as a whole. Except as otherwise noted
below, the listed beneficial owner has sole voting and investment power with
respect to such shares and the address of the listed beneficial owner is that of
the Company.
Number of Percent
Name and Address Shares owned of class
- ----------------- ------------ --------
Steven N. Bronson 141,000,000 50.10%
Estate of Jeffrey Wenig
9 Dickens Avenue
Dix Hills, NY 20,000,000 7.10%
All directors and executive officers
as a group (1 person) 141,000,000 50.10%
Item 12 - Certain Relationships and Related Transactions
The Company utilizes a portion of the premises occupied by Catalyst Financial
Corp., with which Mr. Bronson is a principal, as the Company's executive
offices. Due to the curtailed nature of the Company's operations Catalyst
Financial Corp. has, until further notice, waived the payment of rent by the
Company.
Item 13 - Exhibits List and Reports on Form 8-K
(a) Exhibits
The following exhibits are filed as part of this Annual Report on Form 10-KSB
for the year ended September 30, 1999.
Exhibit No. Exhibit Description
- ----------- -------------------
3.1 Articles of Incorporation of the Company. (1)
3.2 By-Laws of the Company. (1)
10.1 Agreement between the Company and Abtech Industries, Inc.,
dated August 3, 1999.
10.2 First Amendment to the Agreement Dated August 3, 1999, between
the Company and Abtech Industries, Inc., dated September 3,
1999.
- ----------
(1) Incorporated herein by reference to the same numbered Exhibit to the
Company's earlier Form 10-KSB filings under Commission file number 33- 13110-NY.
(b) Reports on Form 8-K
As previously disclosed in the Company's Form 8-K, dated December 29,
1999, the Company dismissed Grant Thornton LLP as its independent accountants
and engaged Kaufman, Rossin & Co. as its new independent accountants, effective
on December 8, 1999. The Company's Form 8-K, dated December 29, 1999 is
incorporated herein by reference.
(c) Financial Statements
The financial statements and related notes of the Company begin on page
3 in the appendix. The report of the independent certified public accountants on
the Company's financial statements begin on page 1 in the appendix.
(d) Financial Statement Schedules
Financial statement schedules have been omitted because of the absence
of conditions under which they are required or because the required material
information is included in the financial statements or related notes included
herein.
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
MedTech Diagnostics, Inc.
January 12, 2000 By: /s/ Steven N. Bronson
-----------------------------
Steven N. Bronson
Sole Officer
In accordance with the Securities Exchange Act of 1934, this report has been
signed below by the following person(s) on behalf of the registrant and in the
capacities and on the dates indicated.
January 12, 2000 by: /s/ Steven N. Bronson
--------------------------------
Steven N. Bronson
Sole Officer (inclusive of Chief
Executive Officer and Principal
Accounting Officer) and Director
<PAGE>
APPENDIX
- ------------------------------------------------------------------------------
MEDTECH DIAGNOSTICS, INC.
FINANCIAL STATEMENTS
YEARS ENDED
SEPTEMBER 30, 1999 AND 1998
- ------------------------------------------------------------------------------
<PAGE>
C O N T E N T S
Page
- ------------------------------------------------------------------------------
INDEPENDENT AUDITORS' REPORTS 1 - 2
FINANCIAL STATEMENTS
Balance Sheet 3
Statements of Operations 4
Statements of Changes in Stockholders' Equity 5
Statements of Cash Flows 6
Notes to Financial Statements 7 - 8
<PAGE>
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors and Stockholders
Medtech Diagnostics, Inc.
We have audited the accompanying statements of operations, changes in
stockholders' equity and cash flows of Medtech Diagnostics, Inc. for the year
ended September 30, 1998. These financial statements are the responsibility of
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
These standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the results of operations and cash flows of Medtech
Diagnostics, Inc. for the year ended September 30, 1998, in conformity with
generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company previously had been in the
development stage and during fiscal 1992 has suspended all operations except for
necessary administrative matters. The Company has not recorded any revenue from
operations and has incurred losses since inception, which raises substantial
doubt about its ability to continue as a going concern. Management's plans in
regard to these matters are described in Note 1 to the financial statements. The
financial statements, referred to above, do not include any adjustments that may
result from the outcome of this uncertainty.
GRANT THORNTON LLP
Melville, New York
January 5, 1999
<PAGE>
INDEPENDENT AUDITORS' REPORT
- ------------------------------------------------------------------------------
To the Board of Directors and Stockholders
MedTech Diagnostics, Inc.
New York, NY
We have audited the balance sheet of MedTech Diagnostics, Inc. as of September
30, 1999, and the related statements of operations, changes in stockholders'
equity and cash flows for the year then ended. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of MedTech Diagnostics, Inc. as of
September 30, 1999, and the results of its operations and its cash flows for the
year then ended in conformity with generally accepted accounting principles.
Miami, Florida
January 3, 2000
<PAGE>
MEDTECH DIAGNOSTICS, INC.
- ------------------------------------------------------------------------------
BALANCE SHEET
SEPTEMBER 30, 1999
ASSETS
- ------------------------------------------------------------------------------
CURRENT ASSETS
Cash and cash equivalents $ 47,677
Loan receivable (Note 4) 1,000
- ------------------------------------------------------------------------------
$ 48,677
- ------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
- ------------------------------------------------------------------------------
CURRENT LIABILITIES
Accounts payable and accrued expenses $ 27,579
- ------------------------------------------------------------------------------
STOCKHOLDERS' EQUITY
Common stock, $.00001 par value; 500,000,000 shares authorized;
281,400,000 shares issued and outstanding 2,814
Capital in excess of par value 1,436,745
Accumulated deficit (1,418,461)
- ------------------------------------------------------------------------------
Total stockholders' equity 21,098
- ------------------------------------------------------------------------------
$ 48,677
- ------------------------------------------------------------------------------
See accompanying notes.
3
<PAGE>
MEDTECH DIAGNOSTICS, INC.
- -------------------------------------------------------------------------------
STATEMENTS OF OPERATIONS
YEARS ENDED SEPTEMBER 30, 1999 and 1998
<TABLE>
<CAPTION>
1999 1998
- ------------------------------------------------------------------------------------------
<S> <C> <C>
INTEREST AND DIVIDEND INCOME $ 10,074 $ 8,337
OPERATING EXPENSES
General and administrative 208,874 13,571
- ------------------------------------------------------------------------------------------
NET LOSS ($ 198,800) ($ 5,234)
- ------------------------------------------------------------------------------------------
NET LOSS PER COMMON SHARE - BASIC AND DILUTED nil nil
- ------------------------------------------------------------------------------------------
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING 281,400,000 281,400,000
- ------------------------------------------------------------------------------------------
</TABLE>
See accompanying notes.
4
<PAGE>
MEDTECH DIAGNOSTICS, INC.
- -------------------------------------------------------------------------------
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
YEARS ENDED SEPTEMBER 30, 1999 AND 1998
<TABLE>
<CAPTION>
Common Stock Capital in
----------------------------- Excess of Accumulated
Shares Amount Par Value Deficit Total
- ---------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Balance at October 1, 1997 281,400,000 $ 2,814 $1,436,745 ( $1,214,427) $ 225,132
Net loss for the year ended
September 30, 1998 - - - ( 5,234) ( 5,234)
- ---------------------------------------------------------------------------------------------------------
Balance at September 30, 1998 281,400,000 2,814 1,436,745 ( 1,219,661) 219,898
Net loss for the year ended
September 30, 1999 - - - ( 198,800) ( 198,800)
- ---------------------------------------------------------------------------------------------------------
Balance at September 30, 1999 281,400,000 $ 2,814 $1,436,745 ( $1,418,461) $ 21,098
- ---------------------------------------------------------------------------------------------------------
</TABLE>
See accompanying notes.
5
<PAGE>
MEDTECH DIAGNOSTICS, INC.
- ---------------------------------------------------------------------------
STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 1999 AND 1998
1999 1998
- -------------------------------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss ($ 198,800) ($ 5,234)
- -------------------------------------------------------------------------------
Adjustments to reconcile net loss to net cash used
in operating activities:
Provision for bad debt 169,000 -
Increase (decrease) in accounts payable and
accrued expenses 24,079 ( 3,250)
- -------------------------------------------------------------------------------
Total adjustments 193,079 ( 3,250)
- -------------------------------------------------------------------------------
Net cash used in operating activities ( 5,721) ( 8,484)
CASH FLOWS FROM INVESTING ACTIVITIES:
Advances evidenced by loan receivable ( 170,000) -
- -------------------------------------------------------------------------------
NET DECREASE IN CASH ( 175,721) ( 8,484)
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR 223,398 231,882
- -------------------------------------------------------------------------------
CASH AND CASH EQUIVALENTS - END OF YEAR $ 47,677 $ 223,398
- -------------------------------------------------------------------------------
See accompanying notes.
6
<PAGE>
MEDTECH DIAGNOSTICS, INC.
NOTES TO FINANCIAL STATEMENTS
- -------------------------------------------------------------------------------
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICES
- -------------------------------------------------------------------------------
Organization and Operations
MedTech Diagnostics, Inc. (the "Company"), previously a
development stage company incorporated under the laws of the
State of Delaware on October 27, 1986, was engaged in research
and testing which it hoped would lead to the development of a
home Pap Test Kit. In 1991, the Company suspended all operations
except for necessary administrative matters. The Company is
currently seeking companies to merge with or acquire in order to
best utilize the Company's corporate structure.
Net Loss Per Common Share
In fiscal 1998, the Company adopted Statement of Financial
Accounting Standards No. 128 ("SFAS No. 128"), Earnings Per
Share, which supersedes Accounting Principles Board Opinion No.
15. Pursuant to SFAS No. 128, net loss per common share is
computed by dividing net loss available to common stockholders by
the weighted-average number of shares outstanding during the
period. Diluted earnings per share would reflect the potential
dilution that could occur if the Company had outstanding
securities or other contracts to issue common stock that could be
exercised or converted into common stock or result in the
issuance of common stock. For the years ended September 30, 1999
and 1998, there is no difference between basic and diluted net
loss per share.
Cash and Cash Equivalents
Cash and cash equivalents consist of cash and all short-term
highly liquid investments that are readily convertible to cash.
The Company, from time to time, maintains cash balances in excess
of federally insured limits.
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with
generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
Income Taxes
Statement of Financial Accounting Standards No. 109 ("SFAS No.
109"), "Accounting for Income Taxes, " requires the use of an
asset and liability approach in accounting for income taxes.
Deferred income taxes reflect the net tax effects of temporary
differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used
for income tax purposes. A valuation allowance is established to
reduce deferred tax assets if it is more likely than not that all
or some portion of such deferred tax assets will not be realized.
The ultimate realization of the deferred tax asset depends on the
Company's ability to generate sufficient taxable income in the
future.
7
<PAGE>
- -------------------------------------------------------------------------------
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICES (Continued)
- -------------------------------------------------------------------------------
At September 30, 1999, the Company had net operating loss
carryforwards of approximately $1,194,000, which expire in
varying amounts beginning September 30, 2002 through September
30, 2019. Federal tax rules impose limitations on the use of net
operating losses following certain changes in ownership. Such a
change of control occurred during the fiscal year ended September
30, 1996. As a result, the Company's ability to utilize the net
operating loss carryforwards existing prior to the ownership
change is subject to an annual limitation of approximately
$14,000 and, accordingly, the maximum net operating loss
presently available is approximately $265,000.
- -------------------------------------------------------------------------------
NOTE 2. RELATED PARTY TRANSACTIONS
- -------------------------------------------------------------------------------
A commonly owned affiliate provides office space and certain
administrative services to the Company at no charge.
- -------------------------------------------------------------------------------
NOTE 3. CHANGE IN OWNERSHIP AND CONTROL
- -------------------------------------------------------------------------------
On June 5, 1996, pursuant to the terms of a Stock Purchase
Agreement (the "Agreement"), Beverly Hills Bancorp sold
141,000,000 shares of the Company's common stock, representing
50.1% of the Company's issued and outstanding common stock, to
Steven N. Bronson and James S. Cassel (the "Purchasers").
In September 1998, Mr. Cassel sold an aggregate of 70,500,000
shares of the Company's common stock, representing Mr. Cassell's
entire interest in the Company, to Mr. Bronson who is the
Company's sole officer and director.
- -------------------------------------------------------------------------------
NOTE 4. LOAN RECEIVABLE
- -------------------------------------------------------------------------------
The Company made two advances, evidenced by a loan receivable,
totaling $170,000 to Abtech Industries, Inc. ("Abtech"), an
intended merger target. The loans are unsecured, bear interest at
10% per annum, and had a scheduled maturity on or before March
31, 2000, unless cancelled in connection with the merger
agreement.
Subsequent to year-end, the merger agreement was cancelled.
Abtech has defaulted under the loan agreement, and the Company is
vigorously seeking recovery of the loan. Because of the Company's
inability to estimate the amount ultimately recoverable from
Abtech, the Company has reduced the carrying value of the
receivable to $1,000 as of September 30, 1999.
8
Exhibit 10.1
As of August 3, 1999
Medtech Diagnostics, Inc.
c/o Catalyst Financial Corp.
16 East 52nd Street
Suite 501
New York, New York 10022
Catalyst Financial Corp.
16 East 52nd Street
Suite 501
New York, New York 10022
Gentlemen:
In accordance with recent discussions, AbTech Industries, Inc., a
Delaware corporation ("AbTech"), hereby confirms its agreement with Medtech
Diagnostics, Inc., a Delaware corporation ("Medtech") and Catalyst Financial
Corp. (the "Placement Agent") as follows:
1. Description of Pre-Offering Merger Activities. AbTech proposes
to merge with and into Medtech, a corporation which is controlled by Steven N.
Bronson, the president of Catalyst. AbTech proposes to consummate such merger
(the "Merger") in the following manner:
(a) AbTech will reduce its outstanding indebtedness,
exclusive of its accounts payable, accrued liabilities, capital leases and the
note due to HGI, to not more than $300,000 by converting such indebtedness into
not more than 775,000 shares of its common stock (the "Debt Conversion").
(b) Medtech will reverse split its outstanding common
stock so that the 281,400,000 outstanding shares will be reduced to 275,612
shares if the minimum number of units are sold in the private placement
described below, and to 237,512 shares if the maximum number of shares are sold
in such placement, provided, however, that, if AbTech issues more than 775,000
shares of its common stock in connection with the Debt Conversion, the size of
the reverse split shall be adjusted to provide each of Medtech's shareholders
with the same pro rata post-Merger ownership interest in the Company that they
would have held if AbTech had issued 775,000 shares of its common stock pursuant
to the Debt Conversion.
(c) AbTech will merge into Medtech, which will change
its name to
<PAGE>
AbTech Industries, Inc., or such other name as shall be mutually acceptable to
AbTech, Medtech and the Placement Agent (such merged entity being hereinafter
referred to as, the "Company"). In connection with that Merger, each outstanding
share of AbTech common stock will be exchanged for one share of the company's
common stock (the "Common Stock"), provided, however, that, if AbTech issues
more than 775,000 shares of its common stock in connection with the Debt
Conversion, each of the investors who purchase the Units hereinbelow described
will receive such number of additional shares of Common Stock as may be
necessary to provide such investors with the same prop rata post-Merger
ownership interest in the Company that they would have held if AbTech had issued
775,000 shares of its common stock pursuant to the Debt Conversion.
(d) The Merger shall be effectuated pursuant to the
terms, and subject to the conditions, of a merger agreement to be negotiated by
Medtech and AbTech with the assistance of their respective counsel, and drafted
by AbTech's counsel (the "Merger Agreement").
(e) AbTech shall not be obligated to consummate the
Merger unless and until the Initial Closing shall be successfully completed.
AbTech and Medtech shall complete the Merger as soon after the date of
completion of the Offering as is reasonably possible.
2. Description of Private Placement Transaction. AbTech proposes to
issue and sell through the Placement Agent, in a transaction exempt from
registration under the Securities Act of 1933, as amended (the "Securities
Act"), to a limited number of investors which meet certain criteria for
"Accredited Investor"status as defined in Rule 501 of Regulation D under the
Securities Act, a Minimum of 25 and a maximum of 50 units (the "Units"), each
Unit consisting of 15,240 shares of AbTech's Common Stock (the "Offering"). The
full terms of the Offering and the securities to be sold in connection therewith
shall be more fully described in the private placement memorandum which will be
distributed to potential investors in the Units (the "Memorandum"). The Common
Stock, Units and the Placement Agent's Warrants (as defined hereinafter) are
hereinafter collectively referred to as the "Securities".
3. Terms of the Offering. The Units will be offered on a "best efforts,
25 Units or none" basis, and thereafter on a "best efforts" basis until a
maximum of 50 Units have been sold by the Placement Agent at a purchase price of
$40,000 per Unit. The Company, in its sole discretion, may accept subscriptions
for fractional Units. All proceeds received by AbTech from subscribers for the
Units offered ("the "Subscribers") will be held in escrow by Continental Stock
Transfer and Trust Company (the "Escrow Agent") and will be deposited by the
Escrow Agent in a non-interest bearing escrow account (the "Escrow Account"). If
at least 25 Units are subscribed on or before a date which shall be not later
than 60 days after the date of commencement of the Offering (the "Expiration
Date"), which date may be extended by the mutual consent of AbTech and the
Placement Agent for an additional 30 days (the "Extended Expiration Date"), a
closing (the "Initial Closing") will be held as soon as practicable after the
subscription documents for such Units have been accepted by AbTech and the
Placement
<PAGE>
Agent and the funds held in the Escrow Account will be paid to AbTech on the
date of such Initial Closing (less the Placement Agent's applicable commission,
which will be retained by the Placement Agent and less the fees and expenses of
the Offering). In such event, AbTech may continue to raise additional funds by
offering the balance of the unsold Units (up to 25 additional Units for a
maximum of 50 Units). All such additional sales must be completed not later than
the Expiration Date which date may be extended by the mutual consent of AbTech
and the Placement Agent through the Extended Expiration Date. Unless 25 Units
are subscribed for by the Expiration Date (unless such date is extended to the
extended Expiration Date, pursuant to the mutual consent of AbTech and the
Placement Agent), the Offering will terminate and all subscription proceeds will
be promptly returned to the subscribers without deduction or interest.
4. Interim Financing: Break-up Fee.
(a) In order to assist AbTech in meeting its obligations
prior to the Merger, Medtech shall lend the sum of $150,000 to AbTech. Such loan
shall (i) be unsecured; (ii) be consummated within ten business days after the
date of execution of this Agreement by all parties; (iii) be used by AbTech as
working capital; (iv) bear interest at the rate of 10% per annum; and (v) be
canceled upon consummation of the Merger, or if the Merger is not consummated on
or before March 31, 2000, such loan shall mature on said date.
(b) Anything contained in Section 4(a) to the contrary
notwithstanding, (i) in the event that AbTech does not successfully complete the
Debt Conversion on or before September 1, 1999, the unpaid principal amount of
said loan, together with all accrued, but unpaid interest thereon, shall become
due and payable on September 8, 1999 without further notice or action required
on the part of Medtech or the Placement Agent; and (ii) in the events that
AbTech successfully completes the Debt Conversion on or before September 1,
1999, but (A) refuses to execute, for any reason, the Merger Agreement after it
has been executed by Medtech; and/or (B) terminates the Offering after such loan
has been made and prior to the Initial Closing, the unpaid principal amount of
said loan, together with all accrues, but unpaid interest thereon, and break- up
fee payable to the Placement Agent in the amount of $100,000 shall thereupon
become immediately due and payable without further notice or action required on
the part of Medtech or the Placement Agent.
5. Registration Rights. The Company, within a reasonable time
after completion of the Offering, shall file with the Securities and Exchange
Commission (the "SEC") a registration statement in appropriate form registering
(a) the Common Stock comprising the Units, pursuant to the Securities Act, in
the name of, and for sale by, the investors who shall have purchased them in the
Offering; and (b) the Common Stock underlying the Placement Agents's Warrants
described below, pursuant to the Securities Act, in the name of, and for sale
by, the Placement Agent, or its designees (the "Post- Merger Registration
Statement"). Sales of such securities may be effected from time to time by the
owners thereof in non-underwritten transactions (which may include block
transactions) in the over-the-counter market, in negotiated transactions, or a
combination of such methods of sale, at fixed prices which may be changed, at
market prices prevailing at the time of sale, or at negotiated prices. The
holders of such securities may effect such transactions by selling their
<PAGE>
Common Stock directly to purchasers or to or through broker-dealers (which may
include the Placement Agent) which may act as agents or principals.
6. Appointment of the Placement Agent. On the basis of the
representations, warranties, covenants and agreement of the Placement Agent
contained herein and subject to the conditions contained herein, AbTech hereby
appoints the Placement Agent as its agent to offer and sell the Units to
Accredited Investors, on a "best efforts, 25 Units or none" basis, and
thereafter, on a "best efforts" basis until a maximum of 50 Units have been
sold. Prior to the Expiration Date or the Extended Expiration Date, as the case
may be, AbTech shall not appoint any other agent to offer and sell the Units.
The Placement Agents, on the basis of the representations, warranties, covenants
and agreements of AbTech contained herein, and subject to the conditions
contained herein, accepts such appointment and agrees to use its best efforts to
sell the Units. It is understood that the Placement Agent has no commitment to
sell the Units other to use its best efforts.
7. Purchase, Sale and Delivery of Units. On the basis of the
representations and warranties contained herein, and subject to the terms and
conditions set forth herein, the parties agree that:
(a) Regulation D Placement. Neither the offer nor the sale
of the Units will be registered with the SEC. The Units will be offered and sold
in reliance upon the exemption from registration provided by Regulation D ("Reg.
D") adopted under the Securities Act, and will only be sold to "Accredited
Investors" as such term is defined under the Securities Act, and be offered for
sale only in states in which the Units are exempt from qualification or
registration for sale and the conditions for such exemption have been met; and
AbTech will provide the Placement Agent for delivery to all offerees and
purchasers and their representatives, if any, with any information, documents
and instruments which the Placement Agent and AbTech deem necessary to comply
with the rules, regulations, and judicial and administrative interpretations
concerning compliance with applicable federal and state statutes and
regulations.
(b) Subscription for Units. Subscription for Units shall
occur by execution and delivery by the Subscriber of a subscription agreement
(the "Subscription Agreement") in the form annexed to the Memorandum, together
with such other documents and instruments as are set forth in the Memorandum and
payment of the required subscription amount all in accordance with the terms of
the Subscription Agreement.
(c) Distribution of Proceeds: Closings. The proceed of the
Offering will be held in Escrow Account until such funds are released to AbTech
at the Initial Closing and each subsequent closing, if any, of the Offering or
returned to the Subscribers if the Offering is not completed prior to the
Expiration Date or Extended Date, as the case may be. AbTech shall deliver to
the Placement Agent on each closing date, on behalf of the Subscribers, the
certificates evidencing the shares of AbTech's common stock comprising the Units
purchased by the Subscribers thereof against payment therefor, after deducting
the amounts set forth in Section 8 below.
<PAGE>
8. Compensation of Placement Agent. As compensation for the
services to be rendered by the Placement Agent under the Agreement, if the
Offering is completed, the Placement Agent shall receive: (i) a sales commission
equal, in the aggregate, to 10.0% of the gross proceeds from the sale of the
Units, payable by deducting the sales commission from such gross proceeds on
each closing date, and (ii) a non-accountable expense allowance equal to 3.0% of
the gross proceeds derived by AbTech from the sale of the units.
On the date of the Initial Closing, AbTech shall sell to the
Placement Agent, or its designees, for an aggregate price of $.001 per share,
five-year warrants to purchase the number of shares of AbTech's common stock
which, if the Merger was consummated on such a date, be equal to 10% of the
post-Merger issued and outstanding shares of Common Stock. On each subsequent
closing date, AbTech shall sell to the Placement Agent, or it's designees, for
an aggregate price of $.001 per share, five-year warrants to purchase the number
of shares of AbTech common stock issuable pursuant to all other similar warrants
issued by AbTech to the Placement Agent hereunder, would, if the Merger was
consummated on such date, be equal to 10% of the post-Merger issued and
outstanding shares of Common Stock. The aggregate number of shares which shall
be purchasable by the holders of all of such warrants, which are collectively
referred to herein as the "Placement Agent's Warrants," shall not exceed
437,5000 shares if the minimum number of Units are sold in the Offering, and
475,6000 shares if the maximum number of Units are sold in the Offering. The
Placement Agent's Warrants shall provide that, upon exercise thereof after the
Merger has been completed, and payment of the exercise price payable thereunder,
the holder or holders thereof shall be entitled to receive one share of the
Company's Common Stock for each share of AbTech common stock that would have
been issued upon exercise thereof prior to the date of completion of the Merger.
The exercise price of the Placement Agent's Warrants shall be $.01 per share.
The Placement Agent's Warrant shall confer to the holders thereof one demand and
unlimited piggy back registration rights in accordance with such terms, and
subject to such limitations, as the parties and their respective counsel shall
agree upon and specify in such Placement Agent's Warrants or in a separate
registration rights agreement.
During the period beginning on the date of commencement of the Offering
and continuing through the 54th day after the effective date of the Merger,
AbTech hereby grants to the Placement Agent, for itself prior to the Merger, and
for the Company after the Merger, the right to act as AbTech's and or/the
Company's exclusive managing underwriters or placement agents, as the case may
be, in any public offering(s) and/or and private placement(s) to be effectuated
by or on behalf of AbTech, the Company or any subsidiary or affiliate of either
of them provided that the material terms offered by the Placement Agent are no
less favorable than those offered by any other underwriter, broker-dealer, or
placement agent. In the event the Placement Agent elects not to exercise its
right of first refusal and the terms of the proposed financing are subsequently
changed, the Placement Agent shall again be granted the right of first refusal
to act as the exclusive managing underwriter or placement agent, as the case may
be, in any such financing as modified. Notwithstanding anything contained in
this Section to the contrary, nothing hereunder shall obligate the Placement
Agent to participate in any such financing. If the Placement Agent elects not to
exercise its right of first refusal with respect to any proposed financing after
being given the opportunity to do so as hereinabove provided, the right of first
refusal shall expire as to all future financings. With respect to an
<PAGE>
initial public offering of the Company's securities, the Company shall have the
right, for a fee of $50,000, to redeem such right of first refusal from the
Placement Agent.
9. Representations and Warranties of AbTech. The following
representations and warranties shall be binding upon AbTech:
(a) Memorandum. AbTech will, by the time of commencement of
the Offering, have prepared the Memorandum, which will contain information,
accurate as of the date specified therein, of the kind specified by applicable
statutes and regulations. The Memorandum, as of its date and at all times
subsequent thereto up to and including the date of the Initial Closing, will not
include any untrue statement of a material fact, or omit to state any material
fact required to be stated therein or necessary to make the statements therein,
in light of the circumstances in which they were made, not misleading.
(b) Additional Information. AbTech will provide to the
Placement Agent such information, documents and instruments as may be required
under Reg. D for an offer made to Accredited Investors pursuant to Reg. D.
(c) Reg. D. Qualification. AbTech will use its best efforts
to ensure that the offer and sale of the Units has satisfied, and on each
closing date will have satisfied, in all material respects, all of the
requirements of Reg. D.
(d) Finder's Fees. AbTech has not incurred any liability
for any finder's fees or payments in connection with the transaction with the
transaction herein contemplated, except for its obligation to pay a fee to JCM
Capital Corp. ("JCM") with respect to amounts raised by Catalyst pursuant to
this Agreement. AbTech agrees to indemnify the Placement Agent with respect to
any claim by any third party for a finder's fee in connection with the Offering
unless such third party's claim is based upon (i) a claim by JCM with respect to
amounts raised by Catalyst pursuant to this Agreement; or (ii) an alleged
agreement or understanding with the Placement Agent.
(e) Foreign Corrupt Practices Act. AbTech has not,
directly or indirectly, at any time (i) made any contributions to any candidate
for political office in violation of law or failed to disclose fully any such
contribution, or (ii) made any payment to any state, federal or foreign
governmental officer or official , or other person charged with similar public
or quasi-public duties, other than payments or contributions required or allowed
by applicable law. AbTech' internal accounting controls and procedures are
sufficient to cause it to comply in all material respects with the Foreign
Corrupt Practices Act of 1977, as amended.
(f) Outstanding Shares of Common Stocks. Immediately prior
to the commencement of the Offering, the total number and class of securities
which AbTech shall then have issued and outstanding, shall not be more that
2,505,888 shares of its common stock, not including: (i) any shares of AbTech's
common stock to be issued pursuant to the Debt Conversion; (ii) any shares of
AbTech's common stock issuable upon exercise of warrants or options outstanding
on the date hereof; or (iii) any other AbTech security outstanding on the
<PAGE>
date hereof which shall not be converted into AbTech's common stock pursuant to
the Debt Conversion.
10. Covenants of AbTech. The following covenants shall be binding upon
AbTech prior to the Merger, and upon the Company upon completion of the Merger:
(a) Memorandum. AbTech will furnish the Placement Agents,
during the Offering, with as many copies of the Memorandum ( and any amendments
or supplements thereto) as the Placement Agent may reasonably request. If,
during the Offering, any event occurs as a result of which the Memorandum, as
then amended or supplemented, would include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements
made in light of the circumstances in which they were made not misleading, or if
it otherwise shall be necessary to amend or supplement the Memorandum to comply
with applicable law, AbTech will forthwith notify the Placement Agent thereof,
and furnish to the Placement Agent in such quantities as may be reasonably
requested, an amendment, supplement or amended or supplemented Memorandum which
corrects such statements or omissions or causes the Memorandum to comply with
applicable law. No copies of the Memorandum, or any exhibit thereto, or any
material prepared by AbTech in connection with the Offering will be given
without the prior written permission of the Placement Agent, by AbTech or its
counsel or by a principal or agent of AbTech to any person not a party to this
Agreement, unless such person is a director or principal stockholder of, or
directly employed by, AbTech, or unless required by law.
(b) State Securities Registration. AbTech will cause its
counsel to take all necessary action and file all necessary forms and documents
in order to obtain an exemption from qualification or registration of the
Securities for sale under the securities laws of the states in which offers or
sales will be made, such states to be mutually agreed upon between AbTech and
the Placement Agent. AbTech will promptly advise the Placement Agent:
(i) if any securities regulator of any state shall
make a request or suggestion of or to AbTech of any amendment to the Memorandum
or for any additional information, including the nature and substance thereof,
and
(ii) of the issuance of a stop order suspending the
sale of the Units in any state, including the initiation or threatening of any
proceeding for such purpose, and AbTech will use its reasonable best efforts to
prevent the issuance of such a stop order, or if such an order shall be issued,
to obtain the withdrawal thereof at the earliest reasonably practicable date.
AbTech will provide the Placement Agent with any additional
information, documents and instruments which the Placement Agent's counsel shall
determine to be necessary to comply with the rules, regulations and judicial and
administrative interpretations in those states and jurisdictions where the Units
are to be offered for sale or sold for delivery for all offerees and purchasers.
AbTech will file all post-offering forms, documents or materials and take all
other actions required by states in which the Units have been offered or sold.
The Placement Agent will not make offers or sales of the Units in any
jurisdiction in
<PAGE>
which the Units are not exempt from qualification or registration.
(c) Use of Proceeds. AbTech intends to apply the net proceeds
from this Offering in the manner set forth in the Memorandum.
(d) Reg. D Compliance. AbTech will use its reasonable best
efforts to determine whether a Subscriber is an "Accredited Investor", and
AbTech will comply in all respects with the terms and conditions of Reg. D and
applicable state securities laws with respect to the offering and the sale of
the Units to qualified investors.
(e) Repayment of Indebtedness. Prior to the date of the final
closing of the Offering, AbTech shall not repay (or agree to repay) any
indebtedness to any of its stockholders (or incur any indebtedness to any of its
stockholders) other than salaries or other compensation paid in the ordinary
course of business or repayments of indebtedness consistent with past practices,
unless the terms thereof are approved in advance by the Placement Agent.
(f) Reservation of Shares. AbTech will reserve sufficient
shares of its common stock for issuance in connection with the offering and sale
of the Units.
(g) Board of Directors. During the period of five years after
the effective date of the Merger, the Placement Agent shall have the right to
designate a representative to observe meetings of the Company's Board of
Directors or require the Company to use its best efforts to elect the Placement
Agent's nominee to the Company's Board of Directors.
(h) Restrictions on Sale. During the period commencing on the
date of commencement of the Offering and continuing until the first anniversary
of the effective date of the Merger, neither AbTech, prior to the Merger, nor
the Company, subsequent to the Merger, will register any shares of their common
stock for their respective directors, officers and/or principal stockholders
without the prior written consent of the Placement Agent. Moreover, the
management of AbTech will (i) cause each of AbTech's directors and officers;
(ii) use its best efforts to cause each of AbTech's stockholders holding 5,000
or fewer shares of any class of AbTech's capital stock; and (iii) cause each of
AbTech's stockholders holding more than 5,000 shares of any class of AbTech's
capital stock (except Warren Bauer), to agree in writing that, during the one
year period commencing on the effective date of the Post-Merger Registration
Statement, none of them shall publicly sell any shares of AbTech's capital stock
or the Common Stock of the Company to be issued to them in exchange therefor
upon completion of the Merger.
11. Representations, Warranties and Covenants of the Placement Agent.
The Placement Agent represents, warrants and covenants to AbTech that:
(a) Duly Registered. The placement Agent is duly
registered, pursuant to the applicable provisions of the Exchange Act, as a
broker-dealer, is a member in good standing of the National Association of
Securities Dealers, Inc. ("NASD"), and is duly registered as a broker-dealer in
such states as the Placement Agent is required to be registered
<PAGE>
in order to complete the Offering contemplated by this Agreement and the
Memorandum. In connection with the offering, the Placement Agent shall have the
right at no additional compensation or cost to AbTech to select co-placement
agents and to form a syndicate of selected dealers who will assist it in the
Offering. Any firm with which the Placement Agent associates will be (i) a fully
registered broker-dealer and a member of the NASD, or (ii) a foreign
broker-dealer and/or a member of a national stock exchange of its country of
origin who is lawfully registered or licensed to act in such jurisdiction.
(b) No General Solicitation or Advertising. The Placement
Agent has not and will not offer or sell the Units by means of general
solicitation or general advertising.
(c) Furnish Memoranda. A reasonable time prior to the date
of the Initial Closing and each closing subsequent thereto, the Placement Agent
will furnish to each offeree of the Units a copy of the Memorandum, each
supplement or amendment thereto, a Subscription Agreement and a Confidential
Subscriber Questionnaire (the "Subscription Documents"). Notwithstanding the
foregoing, the delivery of the Memorandum shall not constitute an offer to sell
the Units to any person. Such sale may be made only upon acceptance by the
Company of a Subscriber's subscription, after a determination that the
Subscriber satisfies all the applicable requirements. The Placement Agent will
not provide any other written information to potential investors in the Units
which has not been approved in advance by AbTech and its counsel.
(d) Reg. D Compliance. The Placement will use its
reasonable best efforts to determine whether a Subscriber is an Accredited
Investor. The Placement Agent is not disqualified from participation in the
Offering by reason of Rules 262(b) and (c) of Regulation A and Reg D. The
Placement Agent will not conduct the Offering contrary to any of the provisions
of Reg. D or corresponding state statutes or regulations.
(e) Blue Sky Compliance. The Placement Agent will solicit
purchasers of the Units only in those jurisdictions where such solicitation
could and can be made in and in which it is so qualified to act and will conduct
the Offering in such jurisdictions in full compliance with all applicable state
statutes and regulations.
(f) Finder's Fees. The Placement Agent has not incurred
any liability for any finder's fees or payments in connection with the
transactions herein contemplated, except as specifically provided in this
Agreement. The Placement Agent agrees to indemnify AbTech and the Company with
respect to any claim by any third party for a finder's fee in connection with
the Offering unless such claim is based upon an alleged agreement or
understanding with the Company.
(g) Subscription Documents. The Placement Agent will
furnish to AbTech copies of all subscription documents completed by the
Subscribers as well as copies of any and all correspondence between the
Placement Agent and the Subscribers.
<PAGE>
12. Conditions to Obligations.
(a) Conditions to Placement Agent's Obligations. The
obligations of the Placement Agent hereunder will be subject to the following
conditions:
(i) Exemption. (A) The Offering contemplated by
this Agreement will be exempt from qualification or registration under the
securities laws of the several states pursuant to Section 10(b) above not later
than the date of the Initial Closing, and (B) at the Initial Closing and each
subsequent closing, no stop order suspending the sale of the Units shall have
been issued, and no proceeding for that purpose shall have been initiated or
threatened;
(ii) No Material Misstatements, Satisfactory
Memorandum. (A) The Memorandum, or any amendment or supplement thereto, shall
not contain an untrue statement of a fact which is material, or omit to state a
fact, which is material and is required to be stated therein, or is necessary to
make the statements therein not misleading, and (B) the Memorandum shall be
reasonably satisfactory in form and in substance to the Placement Agent and its
legal and accounting advisors;
(iii) Compliance with Agreements. AbTech will
have complied with all agreements and satisfied all conditions on its part to be
performed or satisfied in all material respects hereunder at or prior to the
date of the Initial Closing and on the date of each subsequent Closing;
(iv) Corporate Action. AbTech will have taken
all necessary corporate action in connection with the performance by the Company
of its obligations hereunder and thereunder, if applicable, and the consummation
of the Offering;
(v) Opinion of Counsel. On the Date of the
Initial Closing and each subsequent closing date, the Placement Agent will have
received from AbTech's counsel, Squire, Sanders and Dempsey, LLP ("AbTech's
Counsel"), a signed opinion in a form to be mutually agreed upon among AbTech,
the Placement Agent and their respective counsels. In rendering its opinion,
AbTech's Counsel may rely upon (1) opinions of counsel reasonably acceptable to
Placement Agent's counsel with respect to matters relating to the laws of any
jurisdiction other than Delaware and federal law or matters in which AbTech's
Counsel was not significantly involved, (2) the certificated of government
officials and officers of AbTech as to matters of fact, (3) the genuineness of
all signatures, and (4) the authenticity of the books and records of AbTech and
such other qualifications and conditions consistent with AbTech Counsel's
opinion practices.
(vi) Representations and Warranties. The
representations and warranties of AbTech will be, as of the date of the Initial
Closing, and each subsequent closing date, accurate in all material respects.
(vii) Certificate of President. On the Date of
the Initial Closing and each subsequent closing date, AbTech will have delivered
a certificate of its President confirming the satisfaction of the conditions set
forth in this Section 12(a).
<PAGE>
(b) Conditions to AbTech's Obligations. The obligations
of AbTech hereunder will be subject to the following conditions:
(i) Absence of Certain Events. No stop order or
other judicial or administrative action suspending the sale of the Units will
have been issued, and no proceeding for that purpose will have been initiated or
threatened.
(ii) No Material Misstatements. The Memorandum,
or any amendment or supplement thereto, shall not contain an untrue statement of
a fact which is material, or omit to state a fact which is material and is
required to be stated therein or is necessary to make the statements therein, in
light of the circumstances in which they were made, not misleading.
(iii) Compliance with Agreements. The Placement
Agent will have complied with all agreements and satisfied all conditions on its
part to be performed or satisfied hereunder in all material respects at or prior
to the date of the date of the Initial Closing and each subsequent closing date.
(iv) Corporate Action. The placement Agent will
have taken all necessary corporate action, including, without limitation,
obtaining the approval of the Placement Agent's board of directors for the
execution and delivery of this Agreement and the performance by the Placement
Agent of its obligations hereunder and the consummation of the Offering.
(v) Registration. The Placement Agent will
continue to be duly registered as a member in good standing of the NASD and as a
broker-dealer in states required for the Offering.
(vi) Representations and Warranties. The
representations and warranties of the Placement Agent will be, as of the date of
the Initial Closing and each subsequent closing date, accurate in all material
respects.
(vii) Certificate. On the date of the Initial
Closing and each subsequent closing date, the Placement Agent will have
delivered a certificate of its President or Vice President confirming the
satisfaction of the conditions set forth in this Section 12 (b).
13. Expenses of Sale.
(a) AbTech will pay all of its expenses in addition to
those provided in Section 8 herein, incident to the proposed sale and delivery
of Units, whether or not the Offering is consummated, including, without
limitation, (i) the fees, disbursements and expenses of its counsel and
accountants, (ii) all fees and expenses of obtaining exemptions from
registration or qualification of the Units under applicable state securities
laws, and (iii) all other expenses relating to the offering of the Units. The
Memorandum and the exhibits thereto shall be prepared by AbTech's Counsel, whose
costs and expenses shall be paid for by AbTech at the time such services are
rendered.
<PAGE>
(b) If the Offering is not completed because (i) of any
reason solely within the control of AbTech, its management, or its stockholders,
(ii) AbTech unilaterally withdraws the Offering from the Placement Agent for any
reason other than unreasonable delays by the Placement Agent, or (iii) of any
material discrepancy in any representation made to the Placement Agent of the
failure of AbTech to meet any of its material obligations under this Agreement,
then AbTech will be obligated to reimburse the Placement Agent for its
reasonable direct out-of-pocket costs, expenses and legal fees incurred in
connection with the Offering. Otherwise, AbTech will not be obligated to
reimburse the Placement Agent for the Placement Agent's costs and expenses
incurred in connection herewith.
14. Indemnification and Contribution.
(a) Indemnification by AbTech. AbTech agrees to
indemnify and hold harmless the Placement Agent and each person, if any, who
controls the Placement Agent within the meaning of the Securities Act or the
Exchange Act against any losses, claims, damages or liabilities, joint or
several, to which the Placement Agent or such controlling person may become
subject, under the Securities Act or otherwise, to the extent and only to the
extent such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon (i) any untrue statement or alleged
untrue statement of a material fact contained (A) in the Memorandum, or (B) in
any document executed by AbTech filed in any state or other jurisdiction in
order to obtain an exemption from registration or qualification of any or all of
the Units under the securities laws thereof (any such document being hereinafter
called a "Blue Sky Application"), or (ii) the omission or alleged omission to
state in the Memorandum or in any Blue Sky Application a material fact required
to be stated therein or necessary to make the statements therein, under the
circumstances in which they were made, not misleading, and will reimburse the
Placement Agent and each such controlling person in connection with
investigating or defending any such loss, claim, damage, liability or action;
provided, however, that AbTech will not be liable in any such case to the extent
that any such loss, claim, damage or liability arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged omission
made in reliance upon and in conformity with written information furnished to
AbTech by the Placement Agent or Blue Sky counsel specifically for use in the
preparation of the Memorandum or any such Blue Sky Application.
(b) Indemnification by the Placement Agent. The
Placement Agent agrees to indemnify and hold harmless AbTech, its directors and
officers and each person, if any, who controls AbTech within the meaning of the
Securities Act and the Exchange Act against any losses, claims, damages or
liabilities, joint or several, to which AbTech or such controlling person may
become subject, under the Securities Act or otherwise to the extent such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon (i) any untrue statement of a material fact contained (A) in the
Memorandum, or (B) in any Blue Sky Application, or (ii) the omission or alleged
omission to state in the Memorandum or in any Blue Sky Application a material
fact required to be stated therein or necessary to make the statements therein,
under the circumstances in which they were made, not misleading in each case to
the extent but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in
conformity with written information furnished to AbTech by the Placement Agent
or Blue Sky
<PAGE>
counsel specifically for use in the preparation of the Memorandum or any such
Blue Sky Application.
(c) Procedure. Within five (5) business days (unless
shorter period is required) of receipt by an indemnified party under this
Section 14 of notice of the commencement of any action, such indemnified party
will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 14, notify in writing the indemnifying party of the
commencement thereof; and the omission so to notify the indemnifying party will
relieve it from any liability under this Section 14 as to the particular item
for which indemnification is then being sought, but not from any other liability
which it may have to any indemnified party. In case any such action is brought
against any indemnified party, and it notifies an indemnifying party of the
commencement thereof, the indemnifying party will be entitled to participate
therein, and to assume the defense thereof, with counsel who shall be to the
reasonable satisfaction of such indemnified party, and after notice from the
indemnifying party to such indemnified party of its election so to assume the
defense thereof, the indemnifying party will not be liable to such indemnified
party under Section 14 for any legal or other expenses subsequently incurred by
such indemnified party in connection with the defense thereof other than
reasonable costs of investigation. Any such indemnifying party shall not be
liable to any such indemnified party on account of any settlement of any claim
or action effected without the consent of such indemnifying party.
(d) Contribution. If the indemnification provided for
in this Section 14 is unavailable to any indemnified party with respect to any
losses, claims, damages, liabilities or expenses referred to therein, then the
indemnifying party, in lieu of indemnifying such indemnified party, will
contribute to the amount paid or payable by such indemnified party, as a result
of such losses, claims, damages, liabilities or expenses (i) in such proportion
as is appropriate to reflect the relative benefits received by AbTech on the one
hand, and the Placement Agent on the other hand, from the offering of the Units,
or (ii) if the allocation provided by clause (i)above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to as in clause (i) above but also the relative fault
of AbTech on the one hand, and on the Placement Agent on the other hand, in
connection with the statements or omissions which resulted in such losses,
claims, damages, liabilities or expenses as well as any other relevant equitable
considerations. The relative benefits received by AbTech on the one hand, and
the placement Agent on the other hand, shall be deemed to be in the same
proportion as the total proceeds from the Offering (net 0f sales commissions and
non-accountable expense allowance, but before deducting expenses) received by
the Placement Agent. The relative fault of AbTech on the one hand, and the
Placement on the other hand, will be determined with reference to, among other
things, whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by AbTech or
the Placement Agent, and the relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission by the party
responsible for such untrue statement or omission. The amount payable by a party
as a result of the losses, claims, damages, liabilities or expenses referred to
above will be deemed to include , subject to limitations set forth in Section 14
(e) below, any legal or other fees or expenses reasonably incurred by such party
in connection with investigating or defending any action or claim.
<PAGE>
(e) Equitable Considerations. AbTech and the Placement
Agent agree that it would not be just and equitable if contribution pursuant to
this Section 14 were determined by pro rata allocation or by any other method of
allocation which does not take into account the equitable considerations
referred to in the immediately preceding paragraph. No person committing
fraudulent misrepresentation (within the meaning of Section 11 (f) of the
Securities Act) shall be entitled to contribution of indemnification from any
person not committing such fraudulent misrepresentation.
15. Representations and Agreements to Survive Delivery. Except as
otherwise provided in this Agreement, all representations, warranties and
agreements of AbTech and of the Placement Agent herein will survive the delivery
and execution hereof, and shall remain operative and in full force and effect
through the date of the final closing hereunder regardless of any investigation
made by or on behalf of the Placement Agent or any other person who controls
AbTech within the meaning of the Securities Act, and will survive delivery of
the securities constituting the Unite hereunder and any termination of this
Agreement. The provisions of Section 14 hereof shall remain in full force and
effect with respect to any action or proceeding covered thereby until the
indemnifying party shall have satisfied its obligations to the indemnified party
thereunder. Notwithstanding anything contained herein to the contrary, the
Placement Agent will promptly notify AbTech if it becomes aware of any facts
that could be deemed to be a breach of any representation or warranty of AbTech.
16. Termination.
(a) Either the Placement Agent or AbTech will have the
right to terminate this Agreement by giving written notice as herein specified,
at any time, at or prior to the date of the Initial Closing:
(i) If the other shall have failed, refused, or
been unable, at or prior to the Offering Expiration Date, to perform any of its
respective obligations hereunder; or
(ii) If there has occurred an event materially or
adversely affecting the value of the Units or any of the Securities.
(b) If either the Placement Agent or AbTech elects, to
terminate this Agreement pursuant to Subsections (i) or (ii) hereof, notice will
be provided to the non-terminating party promptly by telephone, and such
notification will be confirmed by written notice as provided for in Section 17
below.
17. Notices. Any notice hereunder shall be in writing and shall be
effective when delivered by telecopier or guaranteed overnight delivery, or
mailed by certified or registered mail, postage prepaid, return receipt
requested, to the appropriate party or parties, at the following addresses: if
to the Placement Agent, to Catalyst Financial Corp., 16 East 52nd Street, New
York, New York 10022, Attention: Mr. Steven N. Bronson; if to AbTech prior to
the Merger, to 4110 N. Scottsdale Road, Suite 235, Scotsdale Arizona 85251,
Attention: Glenn R. Rink, President, and if to the Company, c/o Catalyst
Financial Corp., 16 East 52nd Street, New York, New York 10022, Attention: Mr.
Steven N. Bronson, prior to the Merger, and after
<PAGE>
the Merger at 4110 N. Scottsdale Road, Suite 235, Scottsdale, Arizona 85251,
Attention: Glenn R. Rink, President.
18. Parties. This Agreement will be binding upon the Placement Agent
and AbTech prior to the Merger, and upon the Placement Agent and the AbTech
prior to the Merger, and upon the Placement Agent and the Company after the
Merger, and their respective successors and assigns. This Agreement is intended
to be, and is for the sole and exclusive benefit of the parties hereto, and
their respective successors and assigns, and for the benefit of no other person,
and no other person will have any legal or equitable right, remedy or claim
under, or in respect of this Agreement and the parties hereto may not assign any
of their rights or obligations hereunder. No purchaser of any of the Units will
be construed to be a successor or assign merely by reason of such purchase.
19. Amendment and/or Modification. Neither this Agreement, nor any term
or provision hereof, may be changed, waived, discharged, amended, modified or
terminated orally, or in any manner other than by an instrument in writing
signed by each of the parties hereto.
20. Further Assurances. Each party to this Agreement will perform any
and all acts and execute any and all documents as may be necessary and proper
under the circumstances in order to accomplish the intents and purposes of this
Agreement and to carry out its provisions.
21. Validity. In case any term of this Agreement will be held invalid,
illegal or unenforceable, in whole or in part, the validity of any of the other
terms of this Agreement will not in any way be affected thereby.
22. Non-Waiver. The failure of any party hereto to insist upon strict
performance of any of the covenants and agreements herein contained, or to
exercise any option or right herein conferred in any one or more instances, will
not be construed to be a waiver or relinquishment of any such option or right,
or of any other covenants or agreements, and the same will be and remain in full
force and effect.
23. Entire Agreement. This Agreement contains the entire agreement and
understanding of the parties with respect to the entire subject matter hereof,
and there are no representations, inducements, promises or agreements, oral or
otherwise, not embodied herein. Any and all prior discussions, negotiations,
commitments and understanding relating thereto are superseded hereby. There are
no conditions precedent to the effectiveness of this Agreement other than as
stated herein, and there are no related collateral agreements existing between
the parties that are not referred to herein.
24. Counterparts. This Agreement may be executed in counterparts and
each of such counterparts will for all purposes be deemed to be an original, and
such counterparts will together constitute one and the same instrument.
[the balance of this page has been left blank intentionally]
<PAGE>
25. Law. This Agreement will be deemed to have been made and delivered
in New York, New York, and will be governed as to validity, interpretation,
construction, effect and in all other respects by the internal laws of the State
of State of New York, without application of the principals of conflicts of law.
If the foregoing correctly sets forth our understanding, please
indicate in the space provided below for that purpose, whereupon this letter
will constitute a binding agreement between us.
ABTECH INDUSTRIES, INC.
By: /S/ Glenn R. Rink
--------------------------------
Glenn R. Rink, President
CONFIRMED and ACCEPTED this 3rd day of August, 1999 by the undersigned
MEDTECH DIAGNOSTICS, INC.
By: /S/ Steven N. Bronson
--------------------------------
Steven N. Bronson, President
CATALYST FINANCIAL CORP.
By: /S/ Steven N. Bronson
--------------------------------
Steven N. Bronson, President
Exhibit 10.2
FIRST AMENDMENT TO AGREEMENT DATED AUGUST 3, 1999
Amendment dated as of September 3, 1999 (this "Amendment") to the
Agreement dated August 3, 1999 (the "Agreement") among Medtech Diagnostics, Inc.
("Medtech"), AbTech Industries, Inc. ("AbTech") and Catalyst Financial Corp.
WHEREAS, the parties desire to amend certain provisions of the
Agreement, and to confirm the continuing effectiveness of the Agreement as so
amended,
NOW, THEREFORE, in consideration of the foregoing, and the mutual terms
and provisions hereinbelow set forth, it is agreed, as follows:
1. Modification of Indebtedness Reduction Provisions. In order to allow
AbTech the ability to borrow additional funds to meet working capital needs up
to the date of the Initial Closing, Section 1(a) is amended to read as follows:
(a) AbTech will reduce its outstanding indebtedness,
exclusive of its accounts payable, accrued liabilities, capital leases
and the note due to HGI to not more that $300,000 by converting such
indebtedness into not more than 775,000 shares of its common stock (the
"Debt Conversion"). In addition to the $300,000 of outstanding
indebtedness described above, AbTech shall be entitled to incur
additional bridge-loan debt of up to $225,000, excluding any loans made
to AbTech by Med Tech pursuant to Section 4 hereof, for purposes of
meeting AbTech's working capital needs through the date of the Initial
Closing(as defined herein).
2. Modification of Interim Financing Provisions. In recognition of the
fact that Medtech has made two loans to AbTech in the respective principal
amounts of $150,000 and $20,000, instead of one $150,000 loan, as contemplated
by the provisions of Section 4(a) of the Agreement, said section is hereby
amended to read, as follows:
"(a) In order to assist AbTech in meeting its
obligations prior to the Merger, Medtech has made two loans to AbTech
in the respective principal amounts of $150,000 and $20,000. Such loans
(i) are unsecured; (ii) are to be used by AbTech as working capital;
(iii) bear interest at the rate of 10% per annum; and (iv) shall be
cancelled upon consummation of the Merger, or if the Merger is not
consummated on or before March 31, 2000, such loans shall mature on
said date."
3. Extension of Deadline for Completion of Debt Conversion. Section
4(b) of the Agreement is hereby amended to read, as follows:
<PAGE>
"(b) Anything contained in Section 4(a) to the
contrary notwithstanding, (i) in the event that AbTech does not
successfully complete the Debt Conversion on or before September 17,
1999, the unpaid principal amount of said loan, together with all
accrued, but unpaid interest thereon, shall become due and payable on
September 24, 1999 without further notice or action required on the
part of Medtech or the Placement Agent; and (ii) in the events that
AbTech successfully completes the Debt Conversion on or before
September 17, 1999, but (A) refuses to execute, for any reason, the
Merger Agreement after it has been executed by Medtech; and/or (B)
terminates the Offering after such loan has been made and prior to the
Initial Closing, the unpaid principal amount of said loan, together
with all accrued, but unpaid interest thereon, and a break-up fee
payable to the Placement Agent in the amount of $100,000 shall
thereupon become immediately due and payable without further notice or
action required on the part of Medtech or the Placement Agent."
4. Continuation of Effectiveness of Agreement. The parties hereby
confirm that the Agreement, as amended by the provisions of this Amendment,
continues to be in full force and effect.
IN WITNESS WHEREOF, the parties have executed this Amendment to the
Agreement as of the date first above written.
ABTECH INDUSTRIES, INC.
By: /S/ Glenn R. Rink
-------------------------------
Glenn R. Rink, President
MEDTECH DIAGNOSTICS, INC.
By: /S/ Steven N. Bronson
-------------------------------
Steven N. Bronson, President
CATALYST FINANCIAL CORP.
By: /S/ Steven N. Bronson
-------------------------------
Steven N. Bronson, President
